A Phase 3 interventional study of VX-661/Ivacaftor and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 94 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-06-12.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 7th largest by enrollment, is one of 5 that started in 2015, is one of 25 in phase 3, and was the 5th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 5 started in 2015.
This study's enrollment of 248 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 19th largest by enrollment of the 116 interventional ones that give a count, is one of 12 that started in 2015, is one of 62 in phase 3, and was the 39th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of VX-661 in combination with ivacaftor (IVA, VX-770) and IVA monotherapy in participants with Cystic Fibrosis (CF) who are heterozygous for F508del-CFTR allele and a second allele with a CFTR mutation predicted to have residual function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: VX-661/Ivacaftor · Drug: Ivacaftor · Drug: Placebo matched to Ivacaftor
Drug: Ivacaftor · Drug: Placebo matched to VX-661/ ivacaftor
Drug: Placebo matched to VX-661/ ivacaftor · Drug: Placebo matched to Ivacaftor
Drug pages: Tezacaftor · Ivacaftor
Fixed dose combination tablet, oral use
Also known as: VX-661+VX-770
Tablet, oral use
Also known as: IVA, VX-770
Fixed dose combination tablet, oral use
Tablet, oral use
Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Week 4 and Week 8 of each treatment period
Absolute Change From Study Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Week 4 and Week 8
The CFQ-R assessed respiratory symptoms on a scale with scores ranging from 0 to 100; where higher scores indicated fewer symptoms and better health-related quality of life.
Time frame: Baseline, Week 4 and Week 8 of each treatment period
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 28
Relative Change From Study Baseline in ppFEV1 at Average of Week 4 and Week 8
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Week 4 and Week 8 of each treatment period
Absolute Change From Study Baseline in Sweat Chloride at Average of Week 4 and Week 8
Time frame: Baseline, Week 4 and Week 8 of each treatment period
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661), IVA and IVA Metabolite (M1 IVA) After Administration of VX-661/IVA Combination Therapy
Time frame: Pre-morning dose on Week 8 of each treatment period
Ctrough of IVA and IVA Metabolite (M1 IVA) After Administration of IVA Monotherapy
Time frame: Pre-morning dose on Week 8 of each treatment period
A total of 248 participants were enrolled. Out of which, 246 received at least 1 dose of study drug were included in safety set and 244 participants who carried intended cystic fibrosis transmembrane conductance regulator (CFTR) mutations were included in Full analysis set.
| Milestone | First VX-661/IVA, Then IVA | First VX-661/IVA, Then Placebo | First IVA, Then Placebo | First IVA, Then VX- 661/IVA | First Placebo, Then VX- 661/IVA | First Placebo, Then IVA |
|---|---|---|---|---|---|---|
| Started | 41 | 43 | 40 | 42 | 41 | 41 |
| Treated | 41 | 43 | 39 | 42 | 40 | 41 |
| Completed | 38 | 43 | 38 | 41 | 37 | 38 |
| Not completed | 3 | 0 | 2 | 1 | 4 | 3 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Noncompliance | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 0 | 1 | 0 | 1 | 0 |
| Milestone | First VX-661/IVA, Then IVA | First VX-661/IVA, Then Placebo | First IVA, Then Placebo | First IVA, Then VX- 661/IVA | First Placebo, Then VX- 661/IVA | First Placebo, Then IVA |
|---|---|---|---|---|---|---|
| Started | 38 | 43 | 38 | 41 | 37 | 38 |
| Completed | 37 | 43 | 38 | 41 | 37 | 38 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage of predicted FEV1 | Placebo | Ivacaftor | VX-661/IVA |
|---|---|---|---|
| Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8 | -0.3 (-1.2 to 0.6) | 4.4 (3.5 to 5.3) | 6.5 (5.6 to 7.3) |
The CFQ-R assessed respiratory symptoms on a scale with scores ranging from 0 to 100; where higher scores indicated fewer symptoms and better health-related quality of life.
| units on a scale | Placebo | Ivacaftor | VX-661/IVA |
|---|---|---|---|
| Absolute Change From Study Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Week 4 and Week 8 | -1.0 (-2.9 to 1.0) | 8.7 (6.8 to 10.7) | 10.1 (8.2 to 12.1) |
| participants | Placebo | Ivacaftor | VX-661/IVA |
|---|---|---|---|
| Participants with any AEs | 126 | 114 | 117 |
| Participants with SAEs | 14 | 10 | 8 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Placebo | Ivacaftor | VX-661/IVA |
|---|---|---|---|
| Relative Change From Study Baseline in ppFEV1 at Average of Week 4 and Week 8 | -0.2 (-1.7 to 1.4) | 7.9 (6.4 to 9.4) | 11.2 (9.7 to 12.7) |
| millimoles per liter (mmol/L) | Placebo | Ivacaftor | VX-661/IVA |
|---|---|---|---|
| Absolute Change From Study Baseline in Sweat Chloride at Average of Week 4 and Week 8 | -0.4 (-2.3 to 1.5) | -4.9 (-6.7 to -3.0) | -9.9 (-11.8 to -8.0) |
| nanogram per milliliter (ng/mL) | VX-661/IVA |
|---|---|
| VX-661 | 2370 ± 1330 |
| M1 VX-661 | 5230 ± 1940 |
| IVA | 909 ± 530 |
| M1 IVA | 2010 ± 1050 |
| ng/mL | Ivacaftor |
|---|---|
| IVA | 696 ± 435 |
| M1 IVA | 1550 ± 808 |
Collected over Day 1 up to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/162 (0%) | 14/162 (8.6%) | 87/162 (53.7%) |
| Ivacaftor | 0/157 (0%) | 10/157 (6.4%) | 54/157 (34.4%) |
| VX-661/IVA | 0/162 (0%) | 8/162 (4.9%) | 80/162 (49.4%) |
| Event | Placebo | Ivacaftor | VX-661/IVA |
|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 8/162 | 6/157 | 4/162 |
| Blood creatine phosphokinase increasedInvestigations | 0/162 | 2/157 | 0/162 |
| PneumoniaInfections and infestations | 2/162 | 0/157 | 0/162 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/162 | 1/157 | 0/162 |
| Abdominal painGastrointestinal disorders | 2/162 | 0/157 | 0/162 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 0/162 | 1/157 | 0/162 |
| PancreatitisGastrointestinal disorders | 0/162 | 1/157 | 0/162 |
| InfluenzaInfections and infestations | 0/162 | 0/157 | 1/162 |
| Ankle fractureInjury, poisoning and procedural complications | 0/162 | 0/157 | 1/162 |
| HeadacheNervous system disorders | 0/162 | 0/157 | 1/162 |
| Event | Placebo | Ivacaftor | VX-661/IVA |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 30/162 | 17/157 | 23/162 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 25/162 | 14/157 | 19/162 |
| HeadacheNervous system disorders | 13/162 | 11/157 | 18/162 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 12/162 | 17/157 | 12/162 |
| FatigueGeneral disorders | 16/162 | 7/157 | 12/162 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 11/162 | 12/157 | 14/162 |
| NasopharyngitisInfections and infestations | 5/162 | 6/157 | 13/162 |
| DiarrhoeaGastrointestinal disorders | 10/162 | 5/157 | 13/162 |
| PyrexiaGeneral disorders | 12/162 | 2/157 | 8/162 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/162 | 3/157 | 9/162 |
The Full Analysis Set (FAS) was defined as all randomized subjects who carry the intended cystic fibrosis transmembrane conductance regulator (CFTR) mutations and had received at least 1 dose of study drug.
| Age, Categorical(Participants) | First VX- 661/IVA, Then IVA | First VX-661/IVA, Then Placebo | First IVA, Then Placebo | First IVA, Then VX- 661/IVA | First Placebo, Then VX- 661/IVA | First Placebo, Then IVA | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 5 | 6 | 7 | 5 | 5 | 6 | 34 |
| Between 18 and 65 years | 36 | 37 | 33 | 37 | 34 | 35 | 212 |
| >=65 years | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| Sex: Female, Male(Participants) | First VX- 661/IVA, Then IVA | First VX-661/IVA, Then Placebo | First IVA, Then Placebo | First IVA, Then VX- 661/IVA | First Placebo, Then VX- 661/IVA | First Placebo, Then IVA | Total |
|---|---|---|---|---|---|---|---|
| Female | 23 | 25 | 19 | 21 | 23 | 23 | 134 |
| Male | 18 | 18 | 21 | 21 | 18 | 18 | 114 |
| Ethnicity (NIH/OMB)(Participants) | First VX- 661/IVA, Then IVA | First VX-661/IVA, Then Placebo | First IVA, Then Placebo | First IVA, Then VX- 661/IVA | First Placebo, Then VX- 661/IVA | First Placebo, Then IVA | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 3 | 2 | 2 | 9 |
| Not Hispanic or Latino | 40 | 43 | 39 | 39 | 37 | 39 | 237 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | First VX- 661/IVA, Then IVA | First VX-661/IVA, Then Placebo | First IVA, Then Placebo | First IVA, Then VX- 661/IVA | First Placebo, Then VX- 661/IVA | First Placebo, Then IVA | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 0 | 0 | 1 | 3 |
| White | 39 | 42 | 40 | 42 | 39 | 39 | 241 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 2 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Mar 2015, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2018, 1 year 4 months after primary completion. A results delay was requested in Feb 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →